Project Grant R01CA310170
Award Date 5/15/26
Completion Date 4/30/31
Dollars Obligated $671K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate novel microbial-based therapeutic strategies targeting colibactin, a carcinogenic metabolite produced by enteric bacteria associated with colorectal cancer. The research will engineer nonpathogenic commensal microbes to deliver the CLBS resistance protein via bacterial surface...
- Federal Grant Award Summary The University of California, San Diego received a $694,643 Project Grant from the National Cancer Institute (CFDA 93.395, Cancer Treatment Research) awarded on May 7, 2026, with an ultimate completion date of April 30, 2031. The grant supports research targeting the Hippo-YAP/TEAD signaling network in head and neck squamous cell carcinoma (HNSCC). This project addresses the significant clinical challenge of high mortality rates and treatment-related morbidity in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $661,721 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Biology Research program (CFDA 93.396). This award supports research focused on systematic functional mapping and interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins. The project will deliver comprehensive domain and residue-level perturbation screening of IDRs across approximately...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of California, San Diego a $410,115 project grant under the Cancer Biology Research program (CFDA 93.396) beginning August 1, 2025, with completion scheduled for July 31, 2027. This research initiative develops improved preclinical models for pancreatic ductal adenocarcinoma (PDAC) by incorporating three-dimensional high-density type I collagen into tumor modeling systems. The project addresses a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $640,466 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2031. This five-year initiative focuses on developing a novel class of covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project involves designing and genetically incorporating latent...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Grant Award Summary The National Cancer Institute awarded $411,206 to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a project completion date of April 30, 2028. This Project Grant supports the development of small molecule inhibitors targeting the proton-sensing G protein-coupled receptor GPR68 as a novel therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). The research addresses a critical clinical...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
- Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $650,597 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. This research initiative investigates the role of B-cells in generating durable complete responses to checkpoint blockade immunotherapy in head and neck squamous cell carcinoma (HNSCC). The project will deliver three primary research outputs:...